Cadila Healthcare Ltd on Monday said it has received tentative approval from the US FDA to market Levofloxacin tablets of 250 mg, 500 mg and 750 mg in the US market.
The drug a part of the anti-infective segment, is used to treat infections such as pneumonia and chronic bronchitis, the company informed the Bombay Stock Exchange.
The company will market the drug, through its US subsidiary Zydus Pharmaceuticals (USA) Inc, it added.
The branded sales of Levofloxacin tablets in the US market in 2005 was estimated at $295 million.
Do you want to discuss stock tips? Do you know a hot one? Join the Stock Market Investments Discussion Group
© 2025 Rediff.com -